Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

737
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
737
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

608
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
608
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.8K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.8K
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

402
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
402
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

562
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
562
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Importance of Video Urodynamics in Selected Oligo-Anuric Patients Awaiting Renal Transplantation.

Neurourology and urodynamics·2026
Same author

10-yr Outcomes of Senior Clinical Fellowship in Robot-assisted Radical Cystectomy (RARC) with focus on Intracorporeal Ileal Conduit Urinary Diversion: Aggregated Learning Curve Assessment and Achievement of the EAU-Robotic Urology Section (ERUS) RARC Curriculum.

European urology open science·2026
Same author

Robot-assisted simple cystectomy for benign disease with medium-term follow-up: a case series.

Therapeutic advances in urology·2026
Same author

Urodynamics assessment in patients with multiple sclerosis.

BJUI compass·2026
Same author

Robotic ureteric reimplantation for benign disease in a tertiary UK centre: safe and effective.

World journal of urology·2026
Same author

The Long-Term Effects of Sacral Neuromodulation on Urodynamic Parameters in Female Patients With Functional High-Pressure Low-Flow Voiding: A Ticking Time-Bomb?

Neurourology and urodynamics·2026

Related Experiment Video

Updated: Mar 31, 2026

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.6K

PDE-5 Inhibitors for BPH-Associated LUTS.

Philip Brousil, Majid Shabbir, E Zacharakis

  • 1Department of Urology, Guy's and St Thomas' NHS Trust, King's Health Partners, London, UK. arun.sahai@gstt.nhs.uk.

Current Drug Targets
|October 17, 2015
PubMed
Summary

Benign prostatic hyperplasia with lower urinary tract symptoms (BPH-LUTS) and erectile dysfunction (ED) often coexist. Phosphodiesterase type 5 inhibitors (PDE5i) show efficacy in treating both conditions, offering a potential therapeutic option.

More Related Videos

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.9K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

20.5K

Related Experiment Videos

Last Updated: Mar 31, 2026

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.6K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.9K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

20.5K

Area of Science:

  • Urology
  • Andrology
  • Pharmacology

Background:

  • Benign prostatic hyperplasia with lower urinary tract symptoms (BPH-LUTS) significantly impacts quality of life.
  • A strong correlation exists between BPH-LUTS and erectile dysfunction (ED).

Purpose of the Study:

  • To review the common pathogenic pathways of ED and LUTS.
  • To discuss the scientific rationale for using phosphodiesterase type 5 inhibitors (PDE5i) in managing LUTS.
  • To evaluate the efficacy of PDE5i as monotherapy or in combination for LUTS.

Main Methods:

  • Literature review of studies on BPH-LUTS, ED, and PDE5i.
  • Analysis of common pathophysiological mechanisms.
  • Synthesis of clinical trial data on PDE5i efficacy for LUTS.

Main Results:

  • PDE5i are established treatments for ED.
  • Emerging evidence suggests PDE5i benefit men with LUTS.
  • PDE5i may offer a dual therapeutic effect for men with comorbid BPH-LUTS and ED.

Conclusions:

  • Understanding shared pathways of ED and LUTS supports PDE5i use.
  • PDE5i represent a promising therapeutic avenue for BPH-LUTS.
  • Further research can optimize PDE5i treatment strategies for LUTS.